Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
FTY720 is neuroprotective after cuprizone-induced central nervous system demyelination.
Amniotic epithelial cells from the human placenta potently suppress a mouse model of multiple sclerosis.
Validity and variability of the 5-repetition sit-to-stand test in patients with multiple sclerosis.
Axonal Loss in a Rat Model of Optic Neuritis Is Closely Correlated with Visual Evoked Potential Amplitudes Using Electroencephalogram-based Scaling.
Polyunsaturated fatty acids in multiple sclerosis therapy.
First patient enrolled in third Phase III study of oral laquinimod for relapsing-remitting multiple sclerosis
Amelioration of experimental autoimmune encephalomyelitis by anatabine.
Symptoms, Prevalence and Impact of Multiple Sclerosis in Younger Patients: A Multinational Survey.
Substance Name: MEDI 551
Neurofilaments as biomarkers in multiple sclerosis.
FTY720, sphingosine 1-phosphate receptor modulator, selectively radioprotects hippocampal neural stem cells.
Natalizumab treatment reduces endothelial activity in MS patients.
Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis.
Impact of Repeated Topical-Loaded Manganese-Enhanced MRI on the Mouse Visual System.
Impact of acupuncture by using life-energy (qi) oriental needle on the paralysis of rats with experimental autoimmune encephalomyelitis.
Multiple sclerosis shrinks intralesional, and enlarges extralesional, brain parenchymal veins.
Recommendations on diagnosis and treatment of depression in patients with multiple sclerosis.
The invisible gorilla strikes again: sustained inattentional blindness in expert observers.
Severe dystonia as the first manifestation of neuromyelitis optica.
Natalizumab modulates the humoral response against HERV-Wenv73-88 in a follow-up study of Multiple Sclerosis patients.
Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in Korea really differ from that in the Caucasian populations?
Motor vehicle operation in the setting of multiple sclerosis with myelopathy: assessment, adaptive equipment, counseling, and cessation of driving.
Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration.
Multiple sclerosis: basic knowledge and new insights in perioperative management.
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
Pages
« first
‹ previous
…
208
209
210
211
212
213
214
215
216
…
next ›
last »